Craft
  • Home
  •  / Armata Pharmaceuticals
Armata Pharmaceuticals

Armata Pharmaceuticals

Revenue

$409 K

FY, 2014

Market Capitalization

$123.2 M

2022-09-20

Armata Pharmaceuticals Summary

Company summary

Overview
Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for antibiotic-resistant infections. Its main product is AP-SA01 that targets Staphylococcus aureus including multidrug-resistant strains. The company also develops a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals was formed as a result of the merger between C3J Therapeutics and AmpliPhi Biosciences.
Type
Public
Founded
2019
HQ
Marina del Rey, CA, US | view all locations
Website
https://www.armatapharma.com/
Cybersecurity rating
Sectors

Key people

  • Steve Martin

    Steve Martin, Chief Financial Officer

    • Duane Morris

      Duane Morris, Vice President of Operations

      • Odysseas Kostas, Director

        • Robin C. Kramer, Director

          LocationsView all

          1 location detected

          • Marina del Rey, CA HQ

            United States

            4503 Glencoe Ave

          Armata Pharmaceuticals Financials

          Summary financials

          Net income (Q2, 2022)
          ($9.2M)
          Cash (Q2, 2022)
          $37.0M
          EBIT (Q2, 2022)
          ($9.2M)
          Enterprise value
          $125.2M

          Footer menu